^
    11ms
    In the translocation associated RCC, have you also checked which particular gene alterations (TFE3, TFEB, amplified TFEB, ALK etc) were present? #gupath (assuming about 90% will be TFE3 rearranged RCC) (@AkgulMD)
    ALK (Anaplastic lymphoma kinase) • TFE3 • TFEB (Transcription Factor EB 2)
    |
    ALK amplification
    over1year
    @KoheiShitara presenting ctDNA-guided subgroup analysis of PARADIGM; ctDNA guided negative hyperselection markers KRAS, NRAS, BRAF (V600E), PTEN, EGFR (ECD), HER2 and MET amplifications, ALK, RET, or NTRK1 fusions trumped sidedness in response to anti-EGFR benefit #GI23 (@MadhuEluri)
    Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    BRAF V600E • BRAF V600 • NTRK1 fusion • MET amplification • ALK amplification
    almost2years
    CluMPS also visualizes clusters of endogenous proteins. Here we amplify EML4-ALK condensates (@BivonaLabUCSF @TulpuleLab) in lung cancer cells using a binding domain from Gab1. We also track cluster dynamics in response to targeted therapies. (@BugajLab)
    EML4 (EMAP Like 4)
    |
    ALK amplification